Executive Team

Samuel S. Duffey, Esq.
President & CEO
Mr. Duffey was named Biovest’s President in December 2008, and he served as General Counsel to Biovest from April 2003 to February 2013.  Prior to that, Mr. Duffey practiced business law with Duffey & Dolan P.A. beginning in 1992.  From February 2000 to September 2003, Mr. Duffey served as the non-executive Chairman and as a Member of the Board of Directors of Invisa, Inc., a small publicly-held safety company, and from October 2001 to May 2004, Mr. Duffey also served as the non-executive Chairman and as a Member of the Board of Directors of FlashPoint International, Inc., a publicly-held automotive parts company which is currently named Navitrak International Corporation.  Mr. Duffey received his B.A. and J.D. degrees from Drake University.

Brian D. Bottjer
Chief Financial Officer
Mr. Bottjer has served as Biovest’s Controller since June 2007, and was named Chief Financial Officer in January 2011.  From September 2006 to May 2007, Mr. Bottjer was our Senior Accountant.  Prior to that time, from August 2005 to August 2006, Mr. Bottjer was employed as a Controller for Stewart Title Guaranty Company, a provider of title insurance and related services to the real estate and mortgage industries.  From March 2003 to August 2005, Mr. Bottjer served at Raymond James & Associates, Inc., a full service brokerage firm headquartered in St. Petersburg, Florida in a number of roles, including that of manager of financial reporting for certain of the company’s business units.  Mr. Bottjer has also served in a variety of financial reporting and administrative roles at the Home Shopping Network and Allstate Insurance Corporation. Mr. Bottjer is a licensed Certified Public Accountant and received his B.S. in business administration from the State University of New York at Buffalo in 1997.

Carlos F. Santos, Ph.D.
Senior Vice President, Product Development & Regulatory Affairs
In additon to his senior executive role at Biovest, Dr. Santos serves as Chief Science Officer for Accentia Biopharmaceuticals, Inc., Biovest's parent company.  Dr. Santos is managing the development and regulatory strategies for BiovaxID, Biovest’s personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma.  Dr. Santos is credited with making a key discovery in autologous active immunotherapy by identifying the role of the isotype in determining clinical benefit in anti-idiotype B-cell lymphoma vaccination with those results published in the June 2011 Journal of Clinical Oncology.  Dr. Santos is a graduate of the University of Michigan where he earned a Ph.D. in Bioinformatics, and Washington University (St. Louis) where he earned a B.S. in Computer Science.  At the University of Michigan, he developed automated natural language processing systems to integrate high-throughput genomic experimental data with known protein interaction pathways in metastatic prostate cancer progression.  He also led the development of an large-scale automated search and summarization engines for biomedical documents at the University of Michigan’s National Center for Integrative Biomedical Informatics (NCIBI).  And from 1998-2001, he was a researcher at Washington University’s Institute for Biomedical Computing (now the Center for Computational Biology).

Mark Hirschel, Ph.D.
Chief Scientific Officer
Named Chief Scientific Officer in September 2001, Dr. Hirschel directs all of Biovest’s activities related to instruments and cell culture production & services, including validated commercial production of BiovaxID, and managing Biovest’s 35,000 sq. ft. bio-manufacturing facility in Minneapolis.  Prior to being named CSO, he served as Senior Vice President.  As a recognized leader in cell culture production, with a specialty expertise in hollow-fiber systems, Dr. Hirschel served as the Principal Investigator of the National Cell Culture Center at Biovest, producing and delivering more than 1000 cell lines and therapeutic proteins to the National Institutes of Health (NIH) over a 16-year period.   Dr. Hirschel has authored numerous scientific publications, has received several grants and has served on several NIH committees.  Dr. Hirschel holds a B.A. in Biology from Southwest State University (MN), an M.S. in Animal Physiology, and a Ph.D. in Reproductive Physiology from the University of Minnesota.

Douglas W. Calder
Vice President, Strategic Planning & Capital Markets
Mr. Calder brings more than 18-years of life science executive experience as a financial portfolio manager and investor relations professional in managing corporate communications, business development, media strategies and capital markets responsibilities for Biovest.  Mr Calder also served in the same roles for Biovest's parent, Accentia Biopharmaceuticals, Inc, from Dec 2007 through March 2013.  Prior to joining Biovest, Mr. Calder served for 8-years as Investor Relations Officer for Viragen, Inc., a publicly-traded biotechnology company.  Prior to Viragen, he spent nearly 10-years as financial portfolio manager with a biotechnology focus working for the New York Stock Exchange Member Firms: Dean Witter Reynolds; Gruntal & Co.; and Moors & Cabot.  Mr. Calder received his B.A. from Florida State University.

David D. Moser
Director of Legal Affairs & Corporate Secretary
Mr. Moser has served as Biovest’s Director of Legal Affairs since January 2000 and has served as our Secretary since December 31, 2007.  Mr. Moser’s educational background includes a B.A. in Political Science (cum laude, Phi Beta Kappa) from Columbia University and a J.D. (cum laude) from Harvard Law School.  Prior to joining the Company, Mr. Moser was involved in general business, corporate and real estate litigation practice and engaged in residential and commercial real estate brokerage.

Board of Directors

• Ronald Osman, Esq.
• Edmund C. King
• Raphael J. Mannino, Ph.D.
• Peter J. Pappas, Sr.
• Jeffrey A. Scott, M.D.
• John Sitilides